Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Merck, Daiichi scrap FDA application for B7-H3 ADC in lung cancer

In yet another setback to the Merck and Daiichi Sankyo partnership, the companies said they have pulled their FDA accelerated approval application for an antibody-drug conjugate (ADC) in certain small cell lung cancer (SCLC) patients. ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Read the original at endpoints.news →

More in Health & Medicine

More from Monday 28 September →